| 이상지질혈증 치료 약제의 최신지견 |
|
이상학 |
|
|
| Update on the Pharmacologic Agents for Dyslipidemia. |
|
Sang Hak Lee |
|
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. shl1106@yuhs.ac |
|
|
| Abstract |
|
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients. |
| Key Words:
Cholesterol ester transfer proteins, Ezetimibe, Fibric acids, Human PCSK9 protein, Hydroxymethylglutaryl-CoA reductase inhibitors, Niacin, Omega-3 fatty acids |
|
PDF Links
Full text via DOI
Download Citation
